SADIF Analytics releases new summary due diligence report for Pharmagest Inter@ctive

www.sadifanalytics.com

2009-11-10 10:23:13 - SADIF-Investment Analytics has applied its StockMarks™ stock-rating system to Pharmagest Inter@ctive and produced a report, rating the company's attractiveness to long-term investors.

Ilhavo, Portugal – 09/11/2009 – SADIF Investment Analytics, announces a new summary due diligence report covering Pharmagest Inter@ctive (PHA). The report uses SADIF's powerful StockMarks™ stock rating system and contains important analysis for any current or potential Pharmagest Inter@ctive investor.

Report Summary: Pharmagest Inter@ctive is an average quality company with a negative outlook. Pharmagest Inter@ctive has medium business growth and is

run by efficient management. When compared to its closest peer, Cegid Group SA, Pharmagest Inter@ctive shows similar undervaluation and is less likely to outperform the market.

The 8-page report breaks down the Total StockMark into its three components – business, management and price, performing an in-depth analysis of Pharmagest Inter@ctive for long-term investors.

The report has been distributed to Reuters, and forwarded to Yahoo Finance and FT.com. It is available under 'Analyst Reports' from these websites, from multiple professional platforms including Reuters Knowledge, TheMarkets.com, Thomson Research and Capital IQ or directly from SADIF-Investment Analytics at:
www.sadifanalytics.com/stockmarks/company.php?tickerr=PHA&cod_co ..

About SADIF-Investment Analytics:
SADIF-Investment Analytics is an independent investment research company covering sixteen different markets and over 12,000 companies. The StockMarks™ system is based on proven investment principles and is designed to drive long-term shareholder returns.